Kewaunee Scientific's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kewaunee Scientific's ROA in the first quarter of 2026?
Kewaunee Scientific Corporation achieved a return on average assets (ROA) of 4.44 % in its first quarter of 2026, this is above KEQU's average return on assets of 3.68%.
Kewaunee Scientific Corporation assets over the 12 months ending in its first quarter of 2026 are valued at $206 million

ROA decreased relative to the period ending Apr 30 2026, due to the decline in net income.

However, within the Healthcare sector 175 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 910 to 1189.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 31 2026) I. Quarter	(Apr 30 2026) IV. Quarter	(Jan 31 2026) III. Quarter	(Oct 31 2025) II. Quarter	(Jul 31 2025) I. Quarter
Y / Y Total Assets Change	11.34 %	20.4 %	50.12 %	47.02 %	52.92 %
Y / Y Net Income Change	-41.66 %	-25.37 %	-22.2 %	-15.82 %	41.15 %
Net Income (TTM) in million	9	10	12	12	13
Return On Assets (TTM)	4.44 %	5.21 %	6.14 %	6.88 %	7.82 %
KEQU's Total Ranking	# 1189	# 910	# 832	# 809	# 479
Total Assets (TTM) in million	213	232	193	187	191
Seq. Total Assets Change	-8.48 %	20.4 %	2.94 %	-1.84 %	-1.03 %
Seq. Net Income Change	-50.08 %	243.12 %	-57.6 %	-19.66 %	-36.14 %

KEQU's 5 Years Annual ROA >> Back to KEQU Management Effectiveness >> Compare KEQU ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 6
Sector	# 176
Overall	# 1372

Return On Assets Statistics
High	Average	Low
15.24 %	3.68 %	-9.47 %
(Apr 30 2024)		(Jan 31 2022)

Financial Statements
Kewaunee Scientific's Assets	$ 213 million	KEQU's Balance sheet
Kewaunee Scientific's Income	$ 2 million	Quarterly KEQU's Income Statement
KEQU's Income by Division		See KEQU's Income by Division

Annual Return On Assets	(Apr 30 2026) FY 2026	(Apr 30 2025) FY 2025	(Apr 30 2024) FY 2024	(Apr 30 2023) FY 2023	(Apr 30 2022) FY 2022
Y / Y Total Assets Change	20.4 %	50.12 %	8.05 %	0.18 %	32.78 %
Total Assets in million	232	193	128	119	119
Y / Y Net Income Change	-9.65 %	-39.22 %	1302.28 %	-	-
Net Income in million	10	12	19	1	-6
Annual Return On Assets	4.51 %	6.01 %	14.83 %	1.14 %	-5.06 %

KEQU's 5 Years Annual ROA >> Back to KEQU Management Effectiveness >> Compare KEQU ROA to its Competitors

Comment on KEQU's ROA in the fiscal year ending 2026

In the fiscal year 2026 Kewaunee Scientific's ROA decreased compared to previous year to 4.51 %, due to deterioration of net income -9.65 % to $10.47 million, from $11.58 million a year ago, as KEQU's assets were $232.19 million.

More Return On Assets Ratios
KEQU's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KEQU's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KEQU's Competitors
Subscribers only: Roa for Kewaunee Scientific's Suppliers
Subscribers only: Return On Assets for KEQU's Customers

You may also want to know
KEQU's Roi	KEQU's Inventory Turnover Ratio	KEQU's Growth Rates	KEQU's Dividend Comparisons
	KEQU's Profitability Ratios	KEQU's Asset Turnover Ratio	KEQU's Dividend Growth
KEQU's Roe	KEQU's Valuation Ratios	KEQU's Financial Strength Ratios	KEQU's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 31 2026, within Healthcare Sector	ROA
Strata Critical Medical Inc	12.18 %
Insulet Corporation	12.13 %
Lantheus Holdings Inc	11.89 %
Ligand Pharmaceuticals Incorporated	11.68 %
Theravance Biopharma inc	11.68 %
Carlisle Companies Incorporated	11.62 %
Encompass Health Corporation	11.60 %
Protagonist Therapeutics inc	11.02 %
Agilent Technologies inc	10.97 %
Prestige Consumer Healthcare Inc	10.90 %
Lemaitre Vascular Inc	10.90 %
Ufp Technologies Inc	10.85 %
Progyny Inc	10.66 %
Regeneron Pharmaceuticals Inc	10.60 %
Johnson and Johnson	10.60 %
Tenet Healthcare Corp	10.49 %
Bristol myers Squibb Company	10.27 %
Solventum Corporation	10.13 %
Globus Medical Inc	10.04 %
Universal Health Services Inc	9.92 %
Entrada Therapeutics Inc	9.51 %
Amgen Inc	9.48 %
National Healthcare Corp	9.28 %
Tactile Systems Technology Inc	9.17 %
Bioventus Inc	9.08 %
Infusystem Holdings Inc	8.63 %
Penumbra Inc	8.63 %
Utah Medical Products Inc	8.50 %
Boston Scientific Corporation	8.34 %
3m Company	8.27 %

Date modified: 2026-09-12T18:36:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.